Regentis Biomaterials Ltd., a regenerative medicine company, develops tissue repair solutions in the United States. The company offers orthopedic treatments using Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GelrinC, is a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. It offers Gelrin is a unique hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Regentis Biomaterials Ltd. was incorporated in 2004 and is based in Herzliya, Israel.